Avacopan is under clinical development by Amgen and currently in Phase II for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease). According to GlobalData, Phase II drugs for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Avacopan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Avacopan (Tavneos) is a selective immunosuppressant. It is formulated as hard capsules for oral route of administration. Tavneos is indicated for the treatment of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main types of ANCA-associated vasculitis, a rare and severe autoimmune renal disease with high unmet medical need.
Avacopan (CCX-168) is under development for the treatment of anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis and Churg-Strauss syndrome, atypical hemolytic uremic syndrome (aHUS), systemic lupus erythematosus (SLE), C3 glomerulopathy (C3G) which includes dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and hidradenitis suppurativa, lupus nephritis. CCX-168 is an orally bioavailable small molecule antagonist of the C5a receptor. The drug candidate is based on the EnabaLink platform. It was also under development for the treatment of IgA nephropathy (Berger's disease).
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Avacopan’s drug-specific PTSR and LoA scores, buy the report here.